{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:29:28Z","timestamp":1787671768250,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007071","name":"Harran University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007071","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glioblastoma is an aggressive primary brain tumor characterized by high recurrence rates and resistance to standard therapies, including temozolomide (TMZ). Emerging evidence suggests that microRNAs (miRNAs) play a critical role in regulating treatment response and tumor progression. In this study, we investigated the effects of TMZ and the JAK inhibitor ruxolitinib, alone and in combination, on miRNA expression profiles in glioblastoma cancer stem cells. miRNA expression levels were analyzed using quantitative real-time PCR, and differential expression was evaluated using the 2\n                    <jats:sup>\u2212\u0394\u0394Ct<\/jats:sup>\n                    method.\u00a0TMZ treatment increased the expression of oncogenic miRNAs, including hsa-miR-19a-3p, hsa-miR-221-3p, and hsa-miR-10a-5p, whereas ruxolitinib treatment reduced their expression levels. Combination treatment attenuated the TMZ-induced upregulation of these miRNAs. Bioinformatics analyses were performed to identify target genes and associated signaling pathways. Predicted targets were obtained using TargetScan and further supported by experimentally validated interactions from miRTarBase. KEGG pathway enrichment analysis revealed significant associations with cancer-related pathways, including PI3K-Akt, MAPK, Wnt, and Hippo signaling pathways. Network analysis highlighted key genes such as BCL2L11, PTEN, and SOCS family members. Overall, our findings suggest that TMZ may induce oncogenic miRNA expression as part of an adaptive response, while ruxolitinib may counteract this effect. Targeting miRNA-mediated regulatory networks in combination with pathway inhibition may represent a promising strategy to overcome therapeutic resistance in glioblastoma.\n                  <\/jats:p>","DOI":"10.1007\/s00210-026-05506-3","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T02:27:55Z","timestamp":1780885675000},"page":"18273-18282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temozolomide and ruxolitinib combination modulates miRNA-associated regulatory networks in glioblastoma stem cells"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6856-4644","authenticated-orcid":false,"given":"Neslihan Pinar","family":"Ozates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4123-4175","authenticated-orcid":false,"given":"Aycan","family":"Asik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5714-7455","authenticated-orcid":false,"given":"Bakiye Goker","family":"Bagca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-4520","authenticated-orcid":false,"given":"Cigir Biray","family":"Avci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"1","key":"5506_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/S13287-021-02231-X","volume":"12","author":"ALV Alves","year":"2021","unstructured":"Alves ALV, Gomes INF, Carloni AC, Rosa MN, da Silva LS, Evangelista AF, Reis RM, Silva VAO (2021) Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives. Stem Cell Res Ther 12(1):206. https:\/\/doi.org\/10.1186\/S13287-021-02231-X","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"5506_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74746-x","volume":"10","author":"Z Areeb","year":"2020","unstructured":"Areeb Z, Stuart SF, West AJ, Gomez J, Nguyen HPT, Paradiso L, Zulkifli A, Jones J, Kaye AH, Morokoff AP, Luwor RB (2020) Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. Scientific Reports 10(1):17768-. https:\/\/doi.org\/10.1038\/s41598-020-74746-x","journal-title":"Scientific Reports"},{"issue":"23","key":"5506_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14235748","volume":"14","author":"LA de Rooij","year":"2022","unstructured":"de Rooij LA, Mastebroek DJ, ten Voorde N, van der Wall E, van Diest PJ, Moelans CB (2022) The microRNA lifecycle in health and cancer. Cancers 14(23):5748. https:\/\/doi.org\/10.3390\/CANCERS14235748","journal-title":"Cancers"},{"issue":"2","key":"5506_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/BRAINSCI13020350\/S1","volume":"13","author":"L Evers","year":"2023","unstructured":"Evers L, Sch\u00e4fer A, Pini R, Zhao K, Stei S, Nimsky C, Bartsch JW (2023) Identification of dysregulated microRNAs in glioblastoma stem-like cells. Brain Sci 13(2):350. https:\/\/doi.org\/10.3390\/BRAINSCI13020350\/S1","journal-title":"Brain Sci"},{"key":"5506_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/S12032-022-01897-4","author":"B Goker Bagca","year":"2022","unstructured":"Goker Bagca B, Ozates NP, Biray Avci C (2022) Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes. Medical Oncology. https:\/\/doi.org\/10.1007\/S12032-022-01897-4","journal-title":"Medical Oncology"},{"key":"5506_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/J.NBD.2026.107330","volume":"221","author":"H Hu","year":"2026","unstructured":"Hu H, Fan X, Wei J, Wang G, Sun B, Lu C, Bao Y, Jiang L (2026) STAT3 signaling as an adaptive hub in glioblastoma: network rewiring, non-coding RNA circuits, and therapeutic vulnerabilities. Neurobiol Dis 221:107330. https:\/\/doi.org\/10.1016\/J.NBD.2026.107330","journal-title":"Neurobiol Dis"},{"key":"5506_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107377","author":"Y Lan","year":"2023","unstructured":"Lan Y, Yang T, Yue Q, Wang Z, Zhong X, Luo X, Zuo B, Zhang M, Zeng T, Liu B, Guo H (2023) IRP1 mediated ferroptosis reverses temozolomide resistance in glioblastoma via affecting LCN2\/FPN1 signaling axis depended on NFKB2. IScience. https:\/\/doi.org\/10.1016\/j.isci.2023.107377","journal-title":"IScience"},{"key":"5506_CR8","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.917082","volume":"25","author":"Q Li","year":"2019","unstructured":"Li Q, Zhang L, Wu S, Huang C, Liu J, Wang P, Cao Y (2019) Bioinformatics analysis identifies microRNAs and target genes associated with prognosis in patients with melanoma. Medical Science Monitor 25:7784. https:\/\/doi.org\/10.12659\/MSM.917082","journal-title":"Medical Science Monitor"},{"issue":"1","key":"5506_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/S40478-025-02046-4","volume":"13","author":"H Li","year":"2025","unstructured":"Li H, Wu Y, Chen Y, Lv J, Qu C, Mei T, Zheng Y, Ye C, Li F, Ge S, Yao A, Jia L (2025) Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights. Acta Neuropathol Commun 13(1):126. https:\/\/doi.org\/10.1186\/S40478-025-02046-4","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"5506_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12935-023-03130-2","volume":"23","author":"Q Liu","year":"2023","unstructured":"Liu Q, Guo Z, Li G, Zhang Y, Liu X, Li B, Wang J, Li X (2023) Cancer stem cells and their niche in cancer progression and therapy. Cancer Cell International 23(1):1\u201312. https:\/\/doi.org\/10.1186\/S12935-023-03130-2","journal-title":"Cancer Cell International"},{"issue":"2","key":"5506_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/EMBOJ\/17.2.384","volume":"17","author":"L O\u2019Connor","year":"1998","unstructured":"O\u2019Connor L, Strasser A, O\u2019Reilly LA, Hausmann G, Adams JM, Cory S, Huang DCS (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17(2):384\u2013395. https:\/\/doi.org\/10.1093\/EMBOJ\/17.2.384","journal-title":"EMBO J"},{"issue":"3","key":"5506_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13030437","volume":"13","author":"A Ou","year":"2021","unstructured":"Ou A, Ott M, Fang D, Heimberger AB (2021) The role and therapeutic targeting of JAK\/STAT signaling in glioblastoma. Cancers 13(3):437. https:\/\/doi.org\/10.3390\/CANCERS13030437","journal-title":"Cancers"},{"issue":"10","key":"5506_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/BIOLOGY12101295","volume":"12","author":"F Pasqualetti","year":"2023","unstructured":"Pasqualetti F, Miniati M, Gonnelli A, Gadducci G, Giannini N, Palagini L, Mancino M, Fuentes T, Paiar F (2023) Cancer stem cells and glioblastoma: time for innovative biomarkers of radio-resistance? Biology 12(10):1295. https:\/\/doi.org\/10.3390\/BIOLOGY12101295","journal-title":"Biology"},{"issue":"7","key":"5506_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ONC.2011.280","volume":"31","author":"C Quintavalle","year":"2011","unstructured":"Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, Del Basso De Caro M, Martinez-Montero JC, Incoronato M, Nuovo G, Croce CM, Condorelli G (2011) miR-221\/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP\u03bc. Oncogene 31(7):858. https:\/\/doi.org\/10.1038\/ONC.2011.280","journal-title":"Oncogene"},{"issue":"55","key":"5506_CR15","doi-asserted-by":"publisher","first-page":"8404","DOI":"10.1038\/SJ.ONC.1206047","volume":"21","author":"SO Rahaman","year":"2002","unstructured":"Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ (2002) Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21(55):8404\u20138413. https:\/\/doi.org\/10.1038\/SJ.ONC.1206047","journal-title":"Oncogene"},{"issue":"1","key":"5506_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/S43556-023-00151-1","volume":"4","author":"A Sarapultsev","year":"2023","unstructured":"Sarapultsev A, Gusev E, Komelkova M, Utepova I, Luo S, Hu D (2023) JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions. Molecular Biomedicine 4(1):40. https:\/\/doi.org\/10.1186\/S43556-023-00151-1","journal-title":"Molecular Biomedicine"},{"issue":"24","key":"5506_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS222413550","volume":"22","author":"ISEE Sati","year":"2021","unstructured":"Sati ISEE, Parhar I (2021) MicroRNAs regulate cell cycle and cell death pathways in glioblastoma. Int J Mol Sci 22(24):13550. https:\/\/doi.org\/10.3390\/IJMS222413550","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5506_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22062960","volume":"22","author":"E Schnabel","year":"2021","unstructured":"Schnabel E, Knoll M, Schwager C, Warta R, Mock A, Campos B, K\u00f6nig L, Jungk C, Wick W, Unterberg A, Debus J, Herold-Mende C, Abdollahi A (2021) Prognostic value of microRNA-221\/2 and 17-92 families in primary glioblastoma patients treated with postoperative radiotherapy. International Journal of Molecular Sciences 22(6):2960. https:\/\/doi.org\/10.3390\/IJMS22062960","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"5506_CR19","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/CAM4.775","volume":"5","author":"A Shea","year":"2016","unstructured":"Shea A, Harish V, Afzal Z, Chijioke J, Kedir H, Dusmatova S, Roy A, Ramalinga M, Harris B, Blancato J, Verma M, Kumar D (2016) MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med 5(8):1917. https:\/\/doi.org\/10.1002\/CAM4.775","journal-title":"Cancer Med"},{"issue":"9","key":"5506_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/S13205-025-04493-1","volume":"15","author":"C Shetty","year":"2025","unstructured":"Shetty C, Tamatta R, Dhas N, Singh AK (2025) Evolving therapeutic strategies in glioblastoma: traditional approaches and novel interventions. 3 Biotech 15(9):318. https:\/\/doi.org\/10.1007\/S13205-025-04493-1","journal-title":"3 Biotech"},{"issue":"1","key":"5506_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","volume":"10","author":"S Singh","year":"2025","unstructured":"Singh S, Dey D, Barik D, Mohapatra I, Kim S, Sharma M, Prasad S, Wang P, Singh A, Singh G (2025) Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Signal Transduct Target Ther 10(1):213. https:\/\/doi.org\/10.1038\/s41392-025-02299-4","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"5506_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.canlet.2010.04.013","volume":"296","author":"K Ujifuku","year":"2010","unstructured":"Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K, Nagata I, Yamashita S (2010) MiR-195, miR-455-3p and miR-10a* are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 296(2):241\u2013248. https:\/\/doi.org\/10.1016\/j.canlet.2010.04.013","journal-title":"Cancer Lett"},{"issue":"7","key":"5506_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/NRC839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489\u2013501. https:\/\/doi.org\/10.1038\/NRC839","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"5506_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/S41419-025-07617-W","volume":"16","author":"P Wang","year":"2025","unstructured":"Wang P, Liao B, Gong S, Guo HY, Zhao L, Liu J, Wu N (2025) Temozolomide promotes glioblastoma stemness expression through senescence-associated reprogramming via HIF1\u03b1\/HIF2\u03b1 regulation. Cell Death Dis 16(1):317. https:\/\/doi.org\/10.1038\/S41419-025-07617-W","journal-title":"Cell Death Dis"},{"issue":"6","key":"5506_CR25","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/J.FEBSLET.2015.02.005","volume":"589","author":"Y Yan","year":"2015","unstructured":"Yan Y, Wang Q, Yan XL, Zhang Y, Li W, Tang F, Li X, Yang P (2015) miR-10a controls glioma migration and invasion through regulating epithelial-mesenchymal transition via EphA8. FEBS Lett 589(6):756\u2013765. https:\/\/doi.org\/10.1016\/J.FEBSLET.2015.02.005","journal-title":"FEBS Lett"},{"issue":"6","key":"5506_CR26","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/NRI2093","volume":"7","author":"A Yoshimura","year":"2007","unstructured":"Yoshimura A, Naka T, Kubo M (2007) SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7(6):454\u2013465. https:\/\/doi.org\/10.1038\/NRI2093","journal-title":"Nat Rev Immunol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05506-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05506-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05506-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:58:16Z","timestamp":1787669896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05506-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5506"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05506-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}